title: Comparison of the effects of biogenic amines on cyclic GMP and cycle AMP levels in mouse cerebellum in vitro.
abstract: Norepinephrine (NE) elevates levels of both 3',5'-guanosine monophosphate (cyclic GMP) and 3',5'-adenosine monophosphate (cyclic AMP) in incubated slices of mouse cerebellum. As little as 1 muM NE is capable of increasing the level of either cyclic nucleotide. Maximal elevations of cyclic AMP and cyclic GMP levels produced by NE are 15- to 40-fold and 2- to 4-fold, respectively. Dopamine, serotonin and histamine, other biogenic amines considered to be neurotransmitters in CNS, have no effect on mouse cerebellum cyclic nucleotide levels except at relatively high (1 mM) concentrations. NE-induced accumulation of cyclic GMP, but not cyclic AMP, is blocked by omission of Ca2+ from the incubation media. Theophylline does not alter the effect of this catecholamine on either cyclic nucleotide. In tissue slices incubated in buffered sucrose or in choline-Krebs buffer, NE is still capable of increasing both cyclic GMP and cyclic AMP levels; however, these elevations are less than those observed in brain slices incubated in Krebs-Ringer buffer. NE, in combination with glutamate, produces supra-additive elevations of both cyclic GMP and cyclic AMP levels. However, NE in combination with adenosine or high levels of K+ only has a synergistic effect on cyclic AMP and not on cyclic AMP and not on cyclic GMP combination. The elevation of cyclic AMP levels produced by NE appears to be mediated via both alpha- and beta-adrenergic receptor sites. In contrast, the receptor site(s) mediating cyclic AMP accumulation do not appear to be either typical alpha- or beta-adrenergic receptors.
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000818:Animals; D001679:Biogenic Amines / Q000494:pharmacology*; D001923:Brain Chemistry / Q000187:drug effects*; D002118:Calcium / Q000494:pharmacology; D002531:Cerebellum / Q000187:drug effects* / Q000378:metabolism; D003470:Culture Media; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D004298:Dopamine / Q000494:pharmacology; D005260:Female; D005971:Glutamates / Q000494:pharmacology; D005998:Glycine / Q000494:pharmacology; D006632:Histamine / Q000494:pharmacology; D008297:Male; D051379:Mice; D009467:Neuromuscular Depolarizing Agents / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D011941:Receptors, Adrenergic; D012701:Serotonin / Q000494:pharmacology; D013806:Theophylline / Q000494:pharmacology; D014443:Tyrosine / Q000097:blood; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
chemical_list: D001679:Biogenic Amines; D003470:Culture Media; D005971:Glutamates; D009467:Neuromuscular Depolarizing Agents; D011941:Receptors, Adrenergic; D012701:Serotonin; D014443:Tyrosine; D005680:gamma-Aminobutyric Acid; D006632:Histamine; D013806:Theophylline; D000242:Cyclic AMP; D006152:Cyclic GMP; D000241:Adenosine; D011188:Potassium; D002118:Calcium; D005998:Glycine; D004298:Dopamine; D009638:Norepinephrine